Ablation using high-intensity focused ultrasound can effectively control some types of localized prostate cancer for five years or longer, according to a study by German researchers.
Ablation using high-intensity focused ultrasound can effectively control some types of localized prostate cancer for five years or longer, according to a study by German researchers.
Dr. Andreas Blana and colleagues at the University of Regensburg's St. Josef Hospital evaluated results from 140 patients with early or intermediate localized prostate cancer who underwent treatment across
Europe between 1997 and 2001. Follow-up prostate biopsies were negative in 86.4% of patients who underwent focused ultrasound ablation, with a five-year PSA-related failure-free survival rate of 77%. The overall disease-free rate at five and seven years was 66% and 59%, respectively. Findings were published online Nov. 5 in European Urology.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.